DekaBank Deutsche Girozentrale Has $296.99 Million Stake in Stryker Corporation $SYK

DekaBank Deutsche Girozentrale increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 752,729 shares of the medical technology company’s stock after purchasing an additional 7,126 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.20% of Stryker worth $296,987,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sachetta LLC boosted its holdings in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Stryker in the first quarter valued at $32,000. Ridgewood Investments LLC lifted its stake in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Stryker during the 1st quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the 1st quarter worth about $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 1.5%

Shares of Stryker stock opened at $374.67 on Monday. The firm has a market capitalization of $143.24 billion, a PE ratio of 49.63, a price-to-earnings-growth ratio of 2.70 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm’s 50 day moving average is $379.40 and its 200 day moving average is $378.85. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is 44.50%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on SYK shares. UBS Group set a $408.00 price target on shares of Stryker in a research report on Monday, October 13th. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Evercore ISI dropped their target price on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Needham & Company LLC boosted their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $431.76.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.